Dr. Andrews’s Appointment Supports Acer’s Progression from Development to Potential Commercialization of Therapies
CAMBRIDGE, Mass., Oct. 05, 2017 (World NEWSWIRE) — Acer Therapeutics Inc., (Nasdaq:ACER), a pharmaceutical organization focused on the acquisition, progress and commercialization of therapies for really serious exceptional and extremely-exceptional conditions with essential unmet health-related need, nowadays declared the appointment of William T. Andrews, M.D., FACP as Main Health-related Officer of the Organization to succeed Robert D. Steiner, M.D. in that place.
“We are happy to welcome Dr. Andrews to the govt management crew, as we go on to properly and quickly progress our lead merchandise applicant, EDSIVO™, a possible existence-preserving treatment for patients with vEDS,” claimed Chris Schelling, CEO and Founder of Acer. “Dr. Andrews brings huge practical experience to this purpose and will be instrumental in getting ready our NDA submission of EDSIVO™, which we anticipate to carry out in the to start with half of 2018, and we glance ahead to his assistance in the health-related marketplace as we system for our following actions. We thank Dr. Steiner for his substantial contributions to Acer for the duration of a essential time in the Company’s growth.”
About William T. Andrews, M.D., FACP
Dr. Andrews joins Acer Therapeutics as Main Health-related Officer immediately after obtaining labored in the biotech/pharmaceutical marketplace for 17 years in both equally Medical Development and Health-related Affairs in numerous therapeutic spots, with a emphasis and substantial practical experience in exceptional conditions. Dr. Andrews has substantial health-related marketplace and merchandise start practical experience, obtaining served as the health-related lead for six merchandise launches, which includes Xopenex HFA®, Brovana®, Alvesco®, Omnaris®, Catena®, and Juxtapid®. Most lately, he offered strategic consulting companies to exceptional sickness companies in Medical Development, Health-related Affairs, Go-To-Marketplace/Launch preparing, and Organization Development/Company System. Earlier, Dr. Andrews held senior leadership positions and positions of escalating obligation at Aegerion Prescription drugs, Santhera Prescription drugs, Sepracor, and ClinQuest. He been given his undergraduate diploma in Biology from Harvard College and his M.D. diploma from Yale College University of Drugs. Dr. Andrews practiced drugs for 7 years full-time and 11 years portion-time in the Boston area as a board-certified Internist and an Attending Medical professional at Brigham and Women’s Healthcare facility, and was on the Medical College at Harvard Health-related University.
About Acer Therapeutics
Acer, headquartered in Cambridge, MA, is a pharmaceutical organization focused on the acquisition, progress and commercialization of therapies for patients with really serious exceptional and extremely-exceptional conditions with essential unmet health-related need. Acer’s late-stage scientific pipeline contains two candidates for severe genetic ailments for which there are couple of or no Food and drug administration-permitted remedies: EDSIVO™ (celiprolol) for vEDS, and ACER-001 (a fully style-masked, quick release formulation of sodium phenylbutyrate) for urea cycle ailments (UCD) and Maple Syrup Urine Illness (MSUD). There are no Food and drug administration-permitted medications for vEDS and MSUD and minimal choices for UCD, which collectively influence more than 4,000 patients in the United States. Acer’s products and solutions have scientific evidence-of-strategy and mechanistic differentiation, and Acer intends to seek approval for them in the U.S. by applying the regulatory pathway founded less than portion 505(b)(2) of the Federal Foods, Drug, and Cosmetic Act, or FFDCA, that permits an applicant to depend for approval at least in portion on third-social gathering information, which is expected to expedite the planning, submission, and approval of a advertising and marketing application.
For more info, pay a visit to www.acertx.com.
This press release includes “ahead-on the lookout statements” that entail significant threats and uncertainties for reasons of the secure harbor offered by the Non-public Securities Litigation Reform Act of 1995. All statements, other than statements of historical details, incorporated in this press release concerning method, upcoming functions, upcoming fiscal place, upcoming profits, projected costs, potential customers, plans and aims of management are ahead-on the lookout statements. Examples of this kind of statements include things like, but are not minimal to, statements relating to the possible for EDSIVO™ (celiprolol) and ACER-001 to safely and securely and effectively concentrate on conditions the adequacy of the firm’s money to guidance its upcoming functions and its capability to properly initiate and complete scientific trials and regulatory submissions the nature, method and emphasis of the organization and the progress, expected timeline and industrial possible of any merchandise candidates of the organization. Acer may perhaps not essentially reach the plans, carry out the intentions or fulfill the anticipations or projections disclosed in the ahead-on the lookout statements and you should not area undue reliance on these ahead-on the lookout statements. These types of statements are centered on management’s current anticipations and entail threats and uncertainties. True outcomes and functionality could differ materially from those people projected in the ahead-on the lookout statements as a outcome of numerous factors, which includes, without having limitation, threats and uncertainties linked with the capability to project upcoming cash utilization and reserves needed for contingent upcoming liabilities and organization functions, the availability of ample methods of the organization to fulfill its organization aims and operational specifications, the actuality that the outcomes of before studies and trials may perhaps not be predictive of upcoming scientific demo outcomes, the protection and sector exclusivity offered by Acer’s mental home, threats connected to the drug progress and the regulatory approval process and the influence of competitive products and solutions and technological adjustments. Acer disclaims any intent or obligation to update these ahead-on the lookout statements to reflect events or instances that exist immediately after the date on which they had been manufactured. You should evaluation added disclosures we make in our filings with the Securities and Trade Commission, which includes our Quarterly Reviews on Form 10-Q and our Once-a-year Report on Form 10-K. You may perhaps entry these files for no demand at http://www.sec.gov.
Investor Make contact with:
Resource: Acer Therapeutics Inc.